Piramal Enterprises has received a GST demand notice, including tax, interest and penalties, amounting to ₹1,502 crore. The notice concerns the company's sale of its pharma business to Piramal Pharma in FY21, along with the transfer of its subsidiary companies for ₹4,487 crore. Piramal called the order "unjustified" and said it would "take appropriate steps" to challenge it.